Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard L Lalonde

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|December 24, 2021
Probability of Success: A Crucial Concept to Inform Decision Making in Pharmaceutical Research and DevelopmentRichard L Lalonde, Carl C Peck
Journal of Pharmacokinetics and Pharmacodynamics|October 24, 2003
Evaluation of mixture modeling with count data using NONMEMBill Frame, Raymond Miller, Richard L Lalonde
Journal of Clinical Pharmacology|December 21, 2007
A perspective on the use of concentration-QT modeling in drug developmentTanya Russell, Steven P Riley, Jack A Cook, et al.
Journal of Clinical Pharmacology|October 1, 2010
Fostering culture and optimizing organizational structure for implementing model-based drug developmentLiping Zhang, Sandra R Allerheiligen, Richard L Lalonde, et al.
Journal of Clinical Pharmacology|January 18, 2008
Performance characteristics for some typical QT study designs under the ICH E-14 guidanceMatthew M Hutmacher, Sunny Chapel, Marilyn A Agin, et al.
Journal of Clinical Pharmacology|October 22, 2009
Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongationSunny Chapel, Matt M Hutmacher, George Haig, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2005
How modeling and simulation have enhanced decision making in new drug developmentRaymond Miller, Wayne Ewy, Brian W Corrigan, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|December 24, 2021
Probability of Success: A Crucial Concept to Inform Decision Making in Pharmaceutical Research and DevelopmentRichard L Lalonde, Carl C Peck
Journal of Pharmacokinetics and Pharmacodynamics|October 24, 2003
Evaluation of mixture modeling with count data using NONMEMBill Frame, Raymond Miller, Richard L Lalonde
Journal of Clinical Pharmacology|December 21, 2007
A perspective on the use of concentration-QT modeling in drug developmentTanya Russell, Steven P Riley, Jack A Cook, et al.
Journal of Clinical Pharmacology|October 1, 2010
Fostering culture and optimizing organizational structure for implementing model-based drug developmentLiping Zhang, Sandra R Allerheiligen, Richard L Lalonde, et al.
Journal of Clinical Pharmacology|January 18, 2008
Performance characteristics for some typical QT study designs under the ICH E-14 guidanceMatthew M Hutmacher, Sunny Chapel, Marilyn A Agin, et al.
Journal of Clinical Pharmacology|October 22, 2009
Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongationSunny Chapel, Matt M Hutmacher, George Haig, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2005
How modeling and simulation have enhanced decision making in new drug developmentRaymond Miller, Wayne Ewy, Brian W Corrigan, et al.
Pageof 1